

# NIH funding opportunities

25 November 2024 (#30)



**Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.**



See all Important Notices, Parent Announcements and Notice of Special Interest below

**Plan your application. Before starting your application attend**

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

**To prepare an application can take *4-18 months*.**

**From submission to receiving a Notice of Award can take *10 months***

## Important Notices

**[NOT-HS-25-006](#) New "FORMS-I" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2025.** The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- PHS 398 Research Training Program Plan
- PHS Fellowship Supplemental Form
- PHS Assignment Request Form
- PHS 398 Cover Page Supplement Form

Application guides for FORMS-I application packages will be posted to the [How to Apply - Application Guide](#) page in November 2024.

**[NOT-NS-25-004](#) National Institute of Neurological Disorders and Stroke ([NINDS](#)) Policy for applications requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) on NIH Notices of Funding Opportunities, [PAR-22-242](#) and [PAR-22-243](#).** Due to the growing cost of individual grant applications and reduced use of the modular budget format, NINDS is faced with a challenging budgetary landscape. To maintain support for as many investigators as possible in this current environment requires careful management of research projects with large budgets. Effective immediately, NINDS will no longer be supporting grant applications requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) submitted in response to [PAR-22-242](#) and [PAR-22-243](#) Notices of Funding Opportunities (NOFOs) and their reissues.

## Parent Announcements

**[NOT-OD-24-099](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates **Modified Expiration Date: January 8, 2025**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

**[NOT-DC-25-003](#) Autoimmune Inner Ear Disease (Clinical Trials Not Allowed).** Autoimmune inner ear disease (AIED) is an inflammatory disorder of the inner ear. It typically presents with unilateral sudden sensorineural hearing loss that can rapidly progress to involve the second ear. The sudden hearing loss may be fluctuating or progressive. AIED may be seen as a primary autoimmune disease, or secondary to other autoimmune diseases including granulomatosis with polyangiitis, Cogan syndrome, rheumatoid arthritis, systemic lupus erythematosus, polyarteritis nodosa, vitiligo, and relapsing polychondritis. While AIED is often associated with elevated inflammatory markers and may be associated with autoantibodies such as antinuclear antibodies (ANA), rheumatoid factor (RF), and the anti-cochlear antibody 68 kilodalton protein (68kD, hsp-70 antibody), diagnostic and prognostic biomarkers for AIED are very limited. This notice applies to due dates on or after February 16, 2025 and subsequent receipt dates through October 17, 2027.

## Notice of Funding Opportunity (NOFO)

**[PAR-25-058](#) Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed).** This Notice of Funding Opportunity (NOFO) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents include small molecules or biologics. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE).

**Date:** February 18, 2025 though to October 20, 2027. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** Direct costs cannot exceed \$499,000 in any one year. Cumulative direct costs for the entire three-year project period may not exceed \$750,000. The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed three years, with no more than two years for the R61 phase and no more than two years for the R33 phase. (For example, a project could have a 1-year R61 and a 2-year R33 or could have a 2-year R61 and a 1-year R33.)

**[PAR-25-059](#) Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed).** This Notice of Funding Opportunity (NOFO) encourages research grant applications to develop in vitro, ex vivo or in vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE).

**Date:** February 18, 2025 though to October 20, 2027. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** Direct costs cannot exceed \$499,000 in any one year. Cumulative direct costs for the entire three-year project period may not exceed \$750,000. The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed three years, with no more than two years for the R61 phase and no more than two years for the R33 phase. (For example, a project could have a 1-year R61 and a 2-year R33 or could have a 2-year R61 and a 1-year R33.)

**[PAR-25-060](#) Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed).** This Notice of Funding Opportunity (NOFO) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this NOFO is to promote a significant improvement in the translational relevance of animal models

or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Models proposed for this NOFO would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

**Date:** February 18, 2025 though to October 20, 2027. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** Direct costs cannot exceed \$499,000 in any one year. Cumulative direct costs for the entire three-year project period may not exceed \$750,000. The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed three years, with no more than two years for the R61 phase and no more than two years for the R33 phase. (For example, a project could have a 1-year R61 and a 2-year R33 or could have a 2-year R61 and a 1-year R33.)

**[PAR-25-130](#) The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed).**

The National Cancer Institute's (NCI) Metastasis Research Network (MetNet) is a collection of U54 Research Centers that support using systems-level approaches to understand pressing questions in metastasis. The overall goal of the MetNet is to advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and cohesive picture of the processes involved. Through this Notice of Funding Opportunity (NOFO), the NCI invites applications for MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level approaches to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing research across the Network.

**Date:** June 20, 2025. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** Application budgets are limited to a maximum of \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. Project periods of up to 5 years may be proposed.

**[PAR-25-213](#) Implementation Research for Multi-morbidity Management in the Context of Non-communicable Diseases in Low- and Middle-Income Countries and US Tribal Populations (R01 Clinical Trial Optional).**

The National Institutes of Health (NIH) participating Institutes, Centers, and Offices (ICOs), in collaboration with the [Global Alliance for Chronic Diseases](#) (GACD), invite applications for implementation research that aims to improve the availability of effective, equitable, efficient, integrated, patient-centered, safe, and timely care for people living with multiple long-term conditions (non-communicable disease (NCD) multimorbidity) in low- and middle-income countries (LMICs) and/or within American Indian/Alaska Native (AI/AN) populations in the United States. This Notice of Funding Opportunity (NOFO) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations," excluding the Fogarty International Center which manages this program but does not support awards). Applications will be accepted from US and World Bank-defined LMIC institutions only.

**Date:** February 07, 2025; November 05, 2025. AIDS: May 07, 2025; January 07, 2026. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. See Section IV.7 below if requesting \$500,000 or more in direct costs in any year (excluding consortium F&A). The maximum project period is 5 years.

**[PAR-25-223](#) Implementation Research for Multi-morbidity Management in the Context of Non-communicable Diseases in Low- and Middle-Income Countries and US Tribal Populations (R61/R33 Clinical Trial Required).**

The National Institutes of Health (NIH) participating Institutes, Centers, and Offices (ICOs), in collaboration with the [Global Alliance for Chronic Diseases](#) (GACD), invite applications for implementation research that aims to improve the availability of effective, equitable, efficient, integrated, patient-centered, safe, and timely care for people living with multiple long-term conditions (non-communicable disease (NCD) multimorbidity) in low- and middle-income countries (LMICs) and/or within American Indian/Alaska Native (AI/AN) populations in the United States. This Notice of Funding Opportunity (NOFO) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. This NOFO uses the bi-phasic, milestone driven R61/R33 grant mechanism. Awards made under this NOFO will initially support a one-year milestone-driven initiation (R61) phase, with possible transition to an implementation (R33) phase of up to four additional years.

Only projects that meet the scientific milestones and award requirements of the R61 phase may transition to the R33 phase. Applications submitted in response to this NOFO must address both the R61 and R33 phases. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations," excluding the Fogarty International Center which manages this program but does not support awards). Applications will be accepted from US and World Bank-defined LMIC institutions only.

**Date:** February 07, 2025; November 05, 2025. AIDS: May 07, 2025; January 07, 2026. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. See Section IV.7 below if requesting \$500,000 or more in direct costs in any year (excluding consortium F&A). The maximum project period is 5 years.

**[RFA-AI-24-069](#) Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trial Not Allowed).** The purpose of this notice of funding opportunity (NOFO) is to solicit applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). The CAPT-CEPs will focus on developing preclinical assays, tools, and models for robust phage therapy research and development (R&D) and advancing phage clinical research.

**Date:** January 28, 2025. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** NIAID intends to commit \$6M in FY 2026 to fund 2-3 awards. Application budgets are not expected to exceed \$1.2M in direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

**[RFA-MH-26-140](#) BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional).** This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support the development of next generation sensor technologies and bioelectronic devices to further the goals of the Brain Behavior Quantification and Synchronization (BBQS) program of the NIH BRAIN Initiative. The BRAIN Initiative BBQS funding opportunities broadly support 1) development of tools for simultaneous, multimodal measurement of behavior within complex, dynamic physical and/or social environments and synchronize these data with simultaneously-recorded neural activity and 2) development of novel conceptual and computational models that capture dynamic behavior-environment relationships across multiple timescales and that can integrate correlated neural activity into the model. More information about the BRAIN Initiative including existing Notices of Funding Opportunities for the BBQS program can be found [here](#). This NOFO focuses exclusively on the development of novel sensor technology and bioelectronic devices related to the BBQS program and follows a recent workshop [BBQS Workshop May 2023](#). This NOFO will foster close interaction between engineers and behavioral scientists in a Research Consortium. Sensor developers in the Consortium will promote rigorous technology design, fabrication, testing, validation, and dissemination of information regarding sensors and bioelectronics toward improving our understanding of human and organismal behavior.

**Date:** June 13, 2025; 2026; 2027. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** NIMH and partner [components](#) intend to commit an estimated total of \$10 million to fund 6-8 awards for each receipt date. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

**[RFA-RM-24-011](#) Pilot projects to enhance utility and usage of data sets from the Molecular Transducers of Physical Activity Consortium (MoTrPAC) (R03 Clinical Trials Not allowed).** The Molecular Transducers of Physical Activity Consortium (MoTrPAC) has made data available through the MoTrPAC Data Hub (<http://MoTrPAC-data.org>). The purpose of this NOFO is to announce the availability of funding to support novel approaches for analyzing MoTrPAC data, to generate hypotheses and catalyze discoveries; for comparing the publicly released MoTrPAC data to other datasets; and for developing analytic pipelines.

**Date:** December 26, 2024. All applications are due by 5:00 PM local time of applicant organization.

**Budget:** The NIH Common Fund (Office of Strategic Coordination) intends to commit up to \$1,000,000 in FY 2025 to fund up to 12 awards. These awards are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$50,000 direct costs and need to reflect the actual needs of the proposed project. The maximum project period for an application submitted under this NOFO is one year.

**[RFA-AI-24-023](#) U.S.-South Africa Program for Collaborative Biomedical Research – Phase 3 (HIV/AIDS) (R01 Clinical Trial Optional).** The purpose of this Notice of Funding Opportunity (NOFO) is to support research projects under Phase 3 of the U.S.-South Africa Program for Collaborative Biomedical Research. Research areas supported under this

program include HIV/AIDS, HIV/AIDS co-morbidities and co-infections, HIV/AIDS-associated implementation science, and HIV/AIDS-associated data science. The hallmark of the U.S.-South Africa program is the development of collaborative partnerships between South African investigators and United States (U.S.) investigators. Through international collaboration, this research will advance scientific discoveries, promote sharing of technologies and approaches, and serve local public health needs and priorities in support of global HIV/AIDS research.

**AIDS Date:** March 12, 2025. All applications are due by 5:00 PM local time of applicant organization. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$3.8 million to fund 8-10 awards. Application budgets are not expected to exceed \$400,000 in direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**[PAR-24-295 Emerging Global Leader Award \(K43 Independent Clinical Trial Required\)](#)**. The goal of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to a low- or middle-income country (LMIC) early career research scientist who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries, with exceptions below (see Section III. Eligibility Information)). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Notice of Funding Opportunity (NOFO) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors. This NOFO is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO [PAR-24-296](#).

**[Roundup of Research Career Development \(K\) Award Resources](#)**

**[Frequently Asked Questions for the Emerging Global Leader Award](#)**

**Date:** December 03, 2024; December 03, 2025, December 03, 2026. All applications are due by 5:00 PM local time of applicant organization. **Letter of Intent due:** 30 days before the application due date.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Award budgets are composed of salary and other program-related expenses. NIH will contribute up to \$100,000 per year toward the salary of the career award recipient for a minimum 75% effort or 9 person months. The requested salary must be consistent both with the established salary structure at the institution and with salaries provided by the institution from its own funds to other staff members of equivalent qualifications, rank, and responsibilities in the department. Confirmation of LMIC institutional salary may be required prior to the issuance of an award. NIH will contribute research development support of up to \$40,000 per year for the award recipient. Salary for mentors, secretarial and administrative assistants, etc. is not allowed. The total project period should be a minimum of 3 years and may not exceed 5 years.

**[PAR-24-296 Emerging Global Leader Award \(K43 Independent Clinical Trial Not Allowed\)](#)**. The goal of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to a low- or middle-income country (LMIC) early career research scientist who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries, with exceptions below (see Section III. Eligibility Information)). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Notice of Funding Opportunity (NOFO) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO [PAR-24-295](#).

**[Roundup of Research Career Development \(K\) Award Resources](#)**

**[Frequently Asked Questions for the Emerging Global Leader Award](#)**

**Date:** December 03, 2024; December 03, 2025, December 03, 2026. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due: 30 days before the application due date.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Award budgets are composed of salary and other program-related expenses. NIH will contribute up to \$100,000 per year toward the salary of the career award recipient for a minimum 75% effort or 9 person months. The requested salary must be consistent both with the established salary structure at the institution and with salaries provided by the institution from its own funds to other staff members of equivalent qualifications, rank, and responsibilities in the department. Confirmation of LMIC institutional salary may be required prior to the issuance of an award. NIH will contribute research development support of up to \$40,000 per year for the award recipient. Salary for mentors, secretarial and administrative assistants, etc. is not allowed. The total project period should be a minimum of 3 years and may not exceed 5 years.

**Faculty of Medicine and Health Sciences**  
**Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)**  
009 K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.

**Enquiries:** [fmhsgmo@sun.ac.za](mailto:fmhsgmo@sun.ac.za)

Add *“Interest in NIH opportunity”* in the subject line.

Add the *notice number with hyperlink* in the text of the email.